Open AccessIdentification of Small Molecule Inhibitors of β-Amyloid Cytotoxicity through a Cell-Based High-Throughput Screening Platform
Author(s) -
Kathleen Seyb,
Eli Schuman,
Jake Ni,
Meiyi Huang,
Mary L. Michaelis,
Marcie A. Glicksman
Publication year - 2008
Publication title -
slas discovery
Language(s) - English
Resource type - Journals
eISSN - 2472-5560
pISSN - 2472-5552
DOI - 10.1177/1087057108323909
Subject(s) - calpain , neurodegeneration , extracellular , intracellular , programmed cell death , cytotoxicity , microbiology and biotechnology , chemistry , amyloid beta , cell culture , enzyme , biochemistry , biology , apoptosis , peptide , in vitro , medicine , disease , genetics
Calpain activation is hypothesized to be an early occurrence in the sequence of events resulting in neurodegeneration, as well as in the signaling pathways linking extracellular accumulation of beta-amyloid (Abeta) peptides and intracellular formation of neurofibrillary tangles. In an effort to identify small molecules that prevent neurodegeneration in Alzheimer's disease by early intervention in the cell death cascade, a cell-based assay in differentiated Sh-SY5Y cells was developed using calpain activity as a read-out for the early stages of death in cells exposed to extracellular Abeta. This assay was optimized for high-throughput screening, and a library of approximately 120,000 compounds was tested. It was expected that the compounds identified as calpain inhibitors would include those that act directly on the enzyme and those that prevented calpain activation by blocking an upstream step in the pathway. In fact, of the compounds that inhibited calpain activation by Abeta with IC(50) values of <10 microM and showed little or no toxicity at concentrations up to 30 microM, none inhibit the calpain enzyme directly.